The First Industry‑Led Meeting Dedicated to Advancing Next‑Generation COPD Therapeutics

The COPD Drug Development Summit is the first and only industry‑driven forum designed to accelerate meaningful innovation in chronic obstructive pulmonary disease.

With the approval of the first biologic therapy marking a historic turning point, COPD R&D is entering a new era, one defined by deeper biological understanding, more precise patient segmentation, and a renewed push toward disease‑modifying treatments.

This summit convenes leading scientists, clinicians, regulatory experts, and biotech innovators to address the scientific and operational barriers that have long constrained progress.

Over three days, attendees will explore the most urgent and promising areas shaping the future of COPD therapeutics.

Core themes include novel target discovery, translational alignment, and smarter clinical trial design that reflects the heterogeneity of COPD endotypes.

The program also examines the limitations of traditional endpoints such as exacerbations and FEV₁, highlighting next‑generation measures, including imaging‑based progression tools, AI‑enabled assessment, and biomarkers capable of capturing early disease activity and therapeutic impact.

With 65+ industry leaders and 16+ expert speakers from organisations including Johnson & Johnson, Sanofi, GSK, AstraZeneca, Merck, Generate Biomedicines, and Ethris, the summit offers a uniquely concentrated environment for scientific exchange and partnership building.

Participants will engage in 7+ hours of structured networking, panel discussions, and case‑study‑driven sessions that illuminate both the opportunities and the remaining challenges in COPD drug development.

Designed for discovery scientists, translational researchers, clinical developers, regulatory strategists, and biotech executives, this event provides a rare chance to shape the next chapter of COPD innovation.

As the field moves toward more personalised, mechanism‑driven approaches, the COPD Drug Development Summit serves as a critical platform for aligning science, strategy, and regulatory confidence to deliver better outcomes for millions of patients worldwide.

Register now: https://ter.li/kvevwxqk